AnteoTech (ADO) H2 2026 earnings summary

Executive summary

• Revenue from ordinary activities decreased 52% year-over-year to $467,589, with total revenue and other income down 10% to $3,129,144.

• Net loss after tax improved by 27% year-over-year to $(4,928,074), compared to $(6,759,135) in the prior year.

• Recurring Life Sciences revenue continued under a five-year supply agreement, with a significant shipment to Serum Institute of India post-period end to be recognized in the next year.

• No dividends were paid or declared for the period.

Financial highlights

• Product sales and contract services revenue fell to $467,589 from $968,878 year-over-year.

• Other income, mainly from R&D tax concessions, increased to $2,598,354 from $2,431,020.

• Total expenses (excluding non-cash items) decreased by $2,040,807, mainly due to lower salaries, professional services, and research costs.

• Basic and diluted EPS improved to $(0.17) from $(0.26) year-over-year.

Outlook and guidance

• Several commercial opportunities in Advanced Battery Technologies are progressing, including joint development agreements and product validation with industry partners.

• Business development in Life Sciences is focused on high-growth markets such as India, Japan, South Korea, and the USA, with ongoing engagement with prospective customers.

• The company is executing market entry strategies and investing in sales and marketing to drive revenue growth.

• Directors believe the group can continue as a going concern, but acknowledge material uncertainty if future capital raising or commercialization efforts are unsuccessful.